About Us
Management Team
Pipeline
CAR T-cell therapies
mAb
Technology/Platform
Technology/Platform
Manufacturing
Publication
Expanded Access
Media
Join Us
Investors
Announcements
Corporate Governance
Listing Documents
Financial Reports
Presentations & Webcasts
Webcasts
Presentations
IR Contact
Contact Us
EN
简
繁
EN
简
繁
EN
简
繁
About Us
Management Team
Pipeline
CAR T-cell therapies
mAb
Technology/Platform
Technology/Platform
Manufacturing
Publication
Expanded Access
Media
Join Us
Investors
Announcements
Corporate Governance
Listing Documents
Financial Reports
Presentations & Webcasts
Webcasts
Presentations
IR Contact
Contact Us
Presentations & Webcasts
Announcements
Corporate Governance
Listing Documents
Financial Reports
Presentations & Webcasts
IR Contact
Webcasts
Presentations
Date
Title
Jun 05, 2022
2022 ASCO | Safety, Tolerability and Preliminary Efficacy Results in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma from a Phase Ib/II Study of CLDN18.2 CAR T‐cell therapy (CT041)
Jun 05, 2022
2022 ASCO | Multicenter Phase 1b Trial of Salvage CT041 CLDN18.2-specific Chimeric Antigen Receptor T Cell Therapy for Patients with Advanced Gastric and Pancreatic Adenocarcinoma
Dec 13, 2021
2021 ASH | Sustainable Efficacy and Safety Results from LUMMICAR STUDY 1: A Phase 1/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Chinese Subjects with Relapsed and/or Refractory Multiple Myeloma
Dec 13, 2021
2021 ASH | Integrated Analysis of B-cell Maturation Antigen-Specific CAR T Cells (CT053) in Relapsed and Refractory Multiple Myeloma Subjects by High-Risk Factors
Sep 19, 2021
2021 ESMO | CLDN 18.2-targeted CAR-T cell therapy (CT041) in patients with cancers of the digestive system
1